期刊
MAYO CLINIC PROCEEDINGS
卷 89, 期 6, 页码 850-858出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.mayocp.2014.02.014
关键词
-
资金
- National Institute of Health [R01 HL083109]
- US Department of Defense [CSR205330/221349]
- California Institute for Regenerative Medicine [RB4-06215]
The clinical reality of cell therapy for heart disease dates back to the 1990s, when autologous skeletal myoblasts were first transplanted into failing hearts during open-chest surgery. Since then, the focus has shifted to bone marrow-derived cells and, more recently, cells extracted from the heart itself. Although progress has been nonlinear and often disheartening, the field has nevertheless made remarkable progress. Six major breakthroughs are notable: (1) the establishment of safety with intracoronary delivery; (2) the finding that therapeutic regeneration is possible; (3) the increase in allogeneic cell therapy; (4) the effect of increasing mechanistic insights; (5) glimmers of clinical efficacy; and (6) the progression to phase 2 and 3 studies. This article individually reviews these landmark developments in detail and concludes that the field has reached a new phase of maturity where the prospect of clinical impact is increasingly imminent. (C) 2014 Mayo Foundation for Medical Education and Research
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据